Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Springer full text link Springer Free PMC article
Full text links

Actions

Share

Meta-Analysis
.2007 Sep;22(9):1335-50.
doi: 10.1007/s11606-007-0251-z. Epub 2007 Jul 10.

The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs

Affiliations
Meta-Analysis

The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs

Nina Buscemi et al. J Gen Intern Med.2007 Sep.

Abstract

Background: Hypnotics have a role in the management of acute insomnia; however, the efficacy and safety of pharmacological interventions in the management of chronic insomnia is unclear.

Objective: The objective of this paper is to conduct a systematic review of the efficacy and safety of drug treatments for chronic insomnia in adults.

Data sources: Twenty-one electronic databases were searched, up to July 2006.

Study selection: Randomized double-blind, placebo-controlled trials were eligible. Quality was assessed using the Jadad scale. Data were pooled using the random effects model.

Data synthesis: One hundred and five studies were included in the review. Sleep onset latency, as measured by polysomnography, was significantly decreased for benzodiazepines (BDZ), (weighted mean difference: -10.0 minutes; 95% CI: -16.6, -3.4), non-benzodiazepines (non-BDZ) (-12.8 minutes; 95% CI: -16.9, -8.8) and antidepressants (ADP) (-7.0 minutes; 95% CI: -10.7, -3.3). Sleep onset latency assessed by sleep diaries was also improved (BDZ: -19.6 minutes; 95% CI: -23.9, -15.3; non-BDZ: -17.0 minutes; 95% CI: -20.0, -14.0; ADP: -12.2 minutes; 95% CI: -22.3, -2.2). Indirect comparisons between drug categories suggest BDZ and non-BDZ have a similar effect. All drug groups had a statistically significant higher risk of harm compared to placebo (BDZ: risk difference [RD]: 0.15; non-BDZ RD: 0.07; and ADP RD: 0.09), although the most commonly reported adverse events were minor. Indirect comparisons suggest that non-BDZ are safer than BDZ.

Conclusions: Benzodiazepines and non-benzodiazepines are effective treatments in the management of chronic insomnia, although they pose a risk of harm. There is also some evidence that antidepressants are effective and that they pose a risk of harm.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study selection and retrieval
Figure 2
Figure 2
Meta-graph of sleep onset latency (minutes) in adults with chronic insomnia: benzodiazepines versus placebo
Figure 3
Figure 3
Meta-graph of sleep onset latency (minutes) in adults with chronic insomnia: non-benzodiazepines versus placebo
Figure 4
Figure 4
Meta-graph of sleep onset latency (minutes) in adults with chronic insomnia: antidepressants versus placebo
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '10737342', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/10737342/'}]}
    2. Sateia MJ, Doghramji K, Hauri P, Morin CM. Evaluation of chronic insomnia. An American Academy of Sleep Medicine Review. Sleep 2000;23:1–66. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1001/jama.262.11.1479', 'is_inner': False, 'url': 'https://doi.org/10.1001/jama.262.11.1479'}, {'type': 'PubMed', 'value': '2769898', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/2769898/'}]}
    2. Ford D, Kamerow D. Epidemiological study of sleep disturbances and psychiatric disorders: an opportunity for prevention. JAMA 1989;262:1479–84. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '9326825', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/9326825/'}]}
    2. Simon GE, VonKorff M. Prevalence, burden, and treatment of insomnia in primary care. Am J Psychiatry. 1997;54:1417–23. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '12224841', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/12224841/'}]}
    2. Leger D, Guilleminault C, Bader G, Levy E, Paillard M. Medical and socio-professional impact of insomnia. Sleep 2002;25:625–9. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '8723370', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/8723370/'}]}
    2. Ohayon M. Epidemiological study on insomnia in the general population. Sleep 1996;19(3 suppl):S7–15. - PubMed

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full text links
Springer full text link Springer Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp